{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:19:00Z","timestamp":1754482740444,"version":"3.41.0"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The significantly improved survivorship in Hodgkin lymphoma is fraught with challenges, including persistent symptoms, secondary health complications, and socio-professional obstacles. This review highlights the need for comprehensive survivorship care plans that include detection of relapse, assessment of long-term side effects, screening for secondary cancers, psychological support, and assistance with socio-professional integration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Cardiovascular diseases, secondary malignancies and other associated risks remains an important problem related to the effective treatment of patients with Hodgkin lymphoma. Furthermore, fertility concerns and endocrine disorders remain prevalent issues posttreatment. An optimal evaluation of the risks before and after treatment is essential to reduce the impact of these side effects on quality of life. Addressing the socio-professional reintegration of survivors, the concept of the \u2018Right to be forgotten\u2019 emerges as a critical consideration. This principle seeks to eliminate discrimination against cancer survivors in accessing financial services and aims for legislative changes to ensure that past cancer diagnosis does not unfairly affect survivors\u2019 futures. Implementation of this \u2018Right to be forgotten\u2019 in the legislature, is currently underway in European countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The focus of survivorship care has shifted towards the holistic management of these long-term outcomes. Quality of life for Hodgkin lymphoma survivors is affected by various treatment-related factors, with evidence suggesting that physical, psychological and socio-professional domains remain impacted years after treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000001072","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T11:00:07Z","timestamp":1721041207000},"page":"360-368","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Survivorship after Hodgkin lymphoma and the right to be forgotten"],"prefix":"10.1097","volume":"36","author":[{"given":"Yana","family":"Stepanishyna","sequence":"first","affiliation":[{"name":"Hematology Department, Institute Jules Bordet"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Meunier","sequence":"additional","affiliation":[{"name":"Founder of Ending discrimination against cancer survivors project, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[{"name":"Hematology Department, Institute Jules Bordet"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMra1712502","article-title":"Cancer survivorship","volume":"379","author":"Shapiro","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.6004\/jnccn.2020.0037","article-title":"NCCN guidelines insights: survivorship, version 2.2020","volume":"18","author":"Denlinger","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","article-title":"Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials","volume":"5","author":"von Tresckow","year":"2018","journal-title":"Lancet Haematol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 Trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/jco.2016.34.3_suppl.6","article-title":"A Dutch nationwide survivorship care program for Hodgkin lymphoma survivors","volume":"34","author":"Van Leeuwen","year":"2016","journal-title":"J Clin Oncol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.3390\/cancers14235960","article-title":"Clinical management of long-term survivors after classical Hodgkin lymphoma and diffuse large B-cell lymphoma","volume":"14","author":"Bari","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/0284186X.2016.1266089","article-title":"Quality of life in long-term and very long-term cancer survivors versuspopulation controls in Germany","volume":"56","author":"Arndta","year":"2017","journal-title":"Acta Oncol"},{"key":"R15-20250526","first-page":"983","article-title":"Constitution of the World Health Organization. 1946","volume":"80","year":"2002","journal-title":"Bull World Health Organ"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.19.03160","article-title":"Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin study group","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s11912-022-01283-3","article-title":"Quality of life and survivorship in lymphoma","volume":"24","author":"Rosenthal","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2012.762977","article-title":"A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the national comprehensive cancer network-functional assessment of cancer therapy - lymphoma symptom index","volume":"54","author":"Hlubocky","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11764-016-0559-y","article-title":"Seven-year follow-up for energy\/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208","volume":"11","author":"Moinpour","year":"2017","journal-title":"J Cancer Surviv"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1200\/JCO.2016.67.7450","article-title":"Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: the impact on treatment outcome and social reintegration","volume":"34","author":"Behringer","year":"2017","journal-title":"J Clin Oncol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00520-023-07717-3","article-title":"Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6","volume":"31","author":"Mian","year":"2023","journal-title":"Support Care Cancer"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.3390\/cancers13133135","article-title":"The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large B-cell lymphoma survivors. A systematic review by the Fondazione Italiana Linfomi","volume":"13","author":"Minoia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdi407","article-title":"A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue","volume":"16","author":"Ng","year":"2005","journal-title":"Ann Oncol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-7-210","article-title":"Physical activity in Hodgkin's lymphoma survivors with and without chronic fatigue compared with the general population \u2013 a cross-sectional study","volume":"7","author":"Oldervoll","year":"2007","journal-title":"BMC Cancer"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12955-016-0515-6","article-title":"Health-related quality of life in Hodgkin lymphoma: a systematic review","volume":"14","author":"Linendoll","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.3390\/cancers13122976","article-title":"Long-term follow-up of classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: aims and methodological approach for Fondazione Italiana Linfomi systematic reviews","volume":"13","author":"Gerardi","year":"2021","journal-title":"Cancers"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2023.11.014","article-title":"Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trial","volume":"35","author":"Ferdinandus","year":"2024","journal-title":"Ann Oncol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1007\/s00520-022-06918-6","article-title":"Assessment of cognitive function in long-term Hodgkin lymphoma survivors, results based on data from a major treatment center in Hungary","volume":"30","author":"Magyari","year":"2022","journal-title":"Support Care Cancer"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/bjh.15448","article-title":"Cognitive impairment in Hodgkin lymphoma survivors","volume":"182","author":"Trachtenberg","year":"2018","journal-title":"Br J Haematol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"137082","DOI":"10.1016\/j.neulet.2023.137082","article-title":"Cognitive impairment associated with Hodgkin's lymphoma and chemotherapy","volume":"797","author":"Fayette","year":"2023","journal-title":"Neuroscience Letters"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1002\/cam4.3298","article-title":"Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials","volume":"9","author":"Andr\u00e9","year":"2020","journal-title":"Cancer Med"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s12094-022-03034-z","article-title":"Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma","volume":"25","author":"Houlihan","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"R33-20250526","first-page":"64","article-title":"Second malignancies in patients with Hodgkin's Lymphoma: half a century of experience","volume":"13","author":"Shbib Dabaja","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.20.02244","article-title":"Development and validation of a breast cancer risk prediction model for childhood cancer survivors treated with chest radiation: a report from the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"key":"R35-20250526","first-page":"101525","article-title":"Best practice & research clinical haematology: screening for breast cancer in Hodgkin lymphoma survivors","volume":"36","author":"Wong","year":"2023","journal-title":"Res Clin Haematol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2012.46.5732","article-title":"Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma","volume":"31","author":"Ng","year":"2013","journal-title":"J Clin Oncol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.20.00562","article-title":"Updated breast cancer surveillance recommendations for female survivors of childhood adolescent, and young adult cancer from the international guideline harmonization group","volume":"38","author":"Mulder","year":"2020","journal-title":"J Clin Oncol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1245\/s10434-022-11947-w","article-title":"Surgical management and contralateral breast cancer risk in women with history of radiation therapy for Hodgkin lymphoma: results from a population-based cohort","volume":"29","author":"Eisenberg","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.34065","article-title":"Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: results from a population-based cohort","volume":"128","author":"Wong","year":"2022","journal-title":"Cancer"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1055-9965.EPI-22-0019","article-title":"Cost-effectiveness of colorectal cancer surveillance in Hodgkin lymphoma survivors treated with procarbazine and\/or infradiaphragmatic radiotherapy","volume":"31","author":"Ykema","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"31967","DOI":"10.1097\/MD.0000000000031967","article-title":"Risk and outcome of second primary malignancy in patients with classical Hodgkin lymphoma","volume":"101","author":"Wong","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/hon.2402","article-title":"Late sequelae in Hodgkin lymphoma survivors","volume":"35","author":"Van Leeuwen","year":"2017","journal-title":"Hematol Oncol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/cancers14010061","article-title":"Late cardiological sequelae and long-term monitoring in classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a systematic review by the Fondazione Italiana Linfomi","volume":"14","author":"Oliva","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/cncr.34375","article-title":"Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors","volume":"128","author":"Lu","year":"2022","journal-title":"Cancer"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO.21.02613","article-title":"Development and validation of risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma","volume":"41","author":"de Vries","year":"2023","journal-title":"J Clin Oncol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/0284186X.2022.2084639","article-title":"Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy","volume":"61","author":"Loap","year":"2022","journal-title":"Acta Oncol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.3390\/cancers15245831","article-title":"Relation between coronary artery calcium score and cardiovascular events in Hodgkin lymphoma survivors: a cross-sectional matched cohort study","volume":"15","author":"Polomski","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/10428194.2021.1999445","article-title":"Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40\u200ayears after treatment","volume":"63","author":"Macklin-Dohertya","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","article-title":"Hodgkin lymphoma: late effects of treatment and guidelines for surveillance","volume":"53","author":"Ng","year":"2016","journal-title":"Semin Hematol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/0284186X.2014.948057","article-title":"Fatigue in male lymphoma survivors differs between diagnostic groups and is associated with latent hypothyroidism","volume":"54","author":"Kiserud","year":"2015","journal-title":"Acta Oncol"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"1064146","DOI":"10.3389\/fendo.2022.1064146","article-title":"Thyroid function disorders and secondary cancer following haematopoietic stem cell transplantation in pediatrics: state of the art and practical recommendations for a risk-based follow-up","volume":"13","author":"Cattoni","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3390\/cancers14061439","article-title":"Late endocrine and metabolic sequelae and long-term monitoring of classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a systematic review by the Fondazione Italiana Linfomi","volume":"14","author":"Di Molfetta","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/humupd\/dmad002","article-title":"Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review","volume":"29","author":"Drechsel","year":"2023","journal-title":"Hum Reprod Update"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ijc.34552","article-title":"Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study","volume":"153","author":"Entrop","year":"2023","journal-title":"Int J Cancer"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/0284186X.2023.2168215","article-title":"Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment","volume":"62","author":"Eikeland","year":"2023","journal-title":"Acta Oncol"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"jrm00163","DOI":"10.2340\/16501977-2810","article-title":"Rehabilitation in patients with lymphoma: an overview of systematic reviews","volume":"53","author":"Amatya","year":"2021","journal-title":"J Rehabil Med"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1186\/s12889-021-11865-8","article-title":"Supporting participation in paid work of cancer survivors and their partners in the Netherlands: protocol of the SusTained Employability in cancer Patients and their partner (STEPS) multicentre randomized controlled trial and cohort study","volume":"21","author":"Zegers","year":"2021","journal-title":"BMC Public Health"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s11764-022-01196-x","article-title":"Tailoring work participation support for cancer survivors using the stages of change: perspectives of (healthcare) professionals and survivors","volume":"17","author":"Zegers","year":"2023","journal-title":"J Cancer Surviv"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2017.08.097","article-title":"Improving provision of care for long-term survivors of lymphoma","volume":"17","author":"Ciavarella","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R61-20250526","first-page":"1","article-title":"Call for action to end discrimination against cancer survivors","volume":"17","author":"Saul","year":"2018","journal-title":"J Can Pol"},{"key":"R62-20250526","first-page":"1","article-title":"A right to be forgotten for cancer survivors. A legal development expected to reflect the medical progress in the fight against cancer","volume":"25","author":"Scocca","year":"2020","journal-title":"J Can Pol"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/1878-0261.13022","article-title":"Challenges and solutions to embed cancer survivorship research and innovation within the EU cancer Mission","volume":"15","author":"Lawler","year":"2021","journal-title":"Mol Oncol"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2021.12.001","article-title":"Towards an EU legislation on the right to be forgotten to access to financial services for cancer survivors","volume":"162","author":"Scocca","year":"2022","journal-title":"Eur J Cancer"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2018.07.003","article-title":"Evolution of survivorship in lymphoma, myeloma and leukemia: metamorphosis of the field into long term follow-up care","volume":"33","author":"Damlaj","year":"2019","journal-title":"Blood Rev"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","article-title":"Long-term complications after hematopoietic cell transplantation","volume":"10","author":"Majhail","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00520-016-3480-z","article-title":"Cognitive function and its relationship to other psychosocial factors in lymphoma survivors","volume":"25","author":"Krolak","year":"2017","journal-title":"Support Care Cancer"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:04:22Z","timestamp":1748300662000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000001072","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"type":"print","value":"1040-8746"},{"type":"electronic","value":"1531-703X"}],"subject":[],"published":{"date-parts":[[2024,6,24]]}}}